XNAS
ABOS
Market cap90mUSD
Jul 18, Last price
1.50USD
1D
1.35%
1Q
66.52%
IPO
-92.60%
Name
Acumen Pharmaceuticals Inc
Chart & Performance
Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | ||||||
Revenues | ||||||
Cost of revenue | 114,017 | 103,456 | 45,406 | |||
Unusual Expense (Income) | ||||||
NOPBT | (114,017) | (103,456) | (45,406) | |||
NOPBT Margin | ||||||
Operating Taxes | (2,381) | |||||
Tax Rate | ||||||
NOPAT | (114,017) | (103,456) | (43,025) | |||
Net income | (102,329) 95.39% | (52,371) 29.39% | (40,475) -77.72% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 7,897 | 121,904 | 3,907 | |||
BB yield | -7.65% | -65.31% | -1.78% | |||
Debt | ||||||
Debt current | 133 | 1,732 | 105 | |||
Long-term debt | 28,882 | 28,771 | 105 | |||
Deferred revenue | ||||||
Other long-term liabilities | 970 | 2,560 | ||||
Net debt | (142,542) | (275,572) | (193,232) | |||
Cash flow | ||||||
Cash from operating activities | (86,215) | (43,064) | (35,153) | |||
CAPEX | (16) | (21) | (161) | |||
Cash from investing activities | 48,027 | (171,671) | 39,185 | |||
Cash from financing activities | 6,928 | 151,753 | 3,907 | |||
FCF | (113,853) | (103,689) | (43,259) | |||
Balance | ||||||
Cash | 171,557 | 243,522 | 177,605 | |||
Long term investments | 62,553 | 15,837 | ||||
Excess cash | 171,557 | 306,075 | 193,442 | |||
Stockholders' equity | (325,169) | (222,480) | (171,174) | |||
Invested Capital | 536,687 | 521,366 | 360,054 | |||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 60,013 | 48,609 | 40,602 | |||
Price | 1.72 -55.21% | 3.84 -28.89% | 5.40 -20.12% | |||
Market cap | 103,223 -44.70% | 186,660 -14.86% | 219,250 -19.86% | |||
EV | (39,319) | (88,912) | 26,018 | |||
EBITDA | (113,839) | (103,272) | (45,237) | |||
EV/EBITDA | 0.35 | 0.86 | ||||
Interest | 4,068 | 2,381 | ||||
Interest/NOPBT |